| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MOR208C310 | 20-35 | Newly-diagnosed diffuse large B-cell lymphoma (DLBCL). |
This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL). |
DSSG Group: Lymphoma
Paradigme (LYMRIT-37-01)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Paradigme (LYMRIT-37-01) | 18-15 | Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment. |
To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects. |